Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer Beats On Profits Through Aggressive Cost Cutting
- Mike Havrilla submits: click to enlarge Pfizer PFE posted an EPS of $0.62 on revenues of just under $12B, which was two cents ahead of consensus earnings estimates and in-line with revenue estimates for the quarter. The company raised its full-year revenue view to $48-$49B while narrowing its earnings estimate to...
- External links 2008-10-21
- Timber Trade: A New Commodity Pool Fund
- Mike Havrilla submits: click to enlarge by Mike Havrilla
- External links 2008-10-21
- Earnings Encore for Amgen?
- Mike Havrilla submits: click to enlarge by Mike Havrilla
- External links 2008-10-22
- Amgen Exceeds Expectations, Again
- Mike Havrilla submits: Shares of Amgen AMGN have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today, Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its...
- External links 2008-10-22
- Commodity Fund That Tracks Global Coal Price
- Mike Havrilla submits: The accompanying table click to enlarge contains a summary and statistics for 16 ETFI global equity indexes and two commodity pool fund ideas, with the short/inverse and defensive themes outpacing the overall market averages over the past year in the midst of ongoing market turmoil around the...
- External links 2008-10-26
- Biogen Reports Another Tysabri Glitsch
- Mike Havrilla submits: click to enlarge After the market close, Biogen BIIB filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new...
- External links 2008-10-30
- Yahoo: Set for an Up $7, Down $2 Trade
- Mike Havrilla submits: As the Google GOOG ad deal is likely to be scrapped, I am looking for the eventual sale of Yahoo YHOO to Microsoft MSFT at around $19-$22 per share, compared to a previous offer in the low $30s. Call option activity is heating up for November in...
- External links 2008-10-31
- Canadian Solar: About to Be Eclipsed?
- Mike Havrilla submits: Despite a trio of downgrades since Halloween, shares of Canadian Solar CSIQ offer an excellent opportunity as a high beta buy if you believe yesterday's late-day market rally will continue. I bought some shares at $5.35 and for a while it looked poised to plunge much lower...
- External links 2008-11-14
- BioSante: Key Support Is Back
- Mike Havrilla submits: Earlier this week BioSante Pharma BPAX reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of...
- External links 2008-11-14
Additional Resources
- FDA, Clinical Trial Calendar Updates: Discovery, Impax Labs
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision...
- External links 2009-04-21
- << Previous
- page 1 of 1
- Next >>
Presented by American Express